NCT03370601

Evaluation of the Clinical and Immunological Impact of Two Therapeutic Strategies in Chronic Inflammatory Diseases

Evaluation of the Clinical and Immunological Impact of Two Therapeutic Strategies (Increasing the Infliximab Dose or Introduction of Immunosuppressive Therapy) in Patients Chronic Inflammatory Bowel Diseases in Loss of Response to Infliximab

• Status: Terminated
• Phase: N/A
• Study type: Interventional
• Enrollment: 9 (actual)
• Sponsor: University Hospital, Lille · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This study evaluates 2 therapeutic strategies (increase infliximab dose or add an immunosuppressant) in patients with inflammatory bowel disease in loss of response to infliximab. Addition of an immunosuppressant may be more efficient at long term and is less expensive.

Conditions

• Inflammatory Bowel Diseases

Interventions

Type	Name	Description
DRUG	Infliximab	Infliximab 10mg/kg every 8 weeks
DRUG	Mercaptopurine	6-mercaptopurine 1 à 1,5 mg/kg
DRUG	Azathioprine	Azathioprine 2 à 2.5mg/kg/j
DRUG	Infliximab	Infliximab 5mg/kg every 8 weeks

Timeline

• Start date: 2017-01-03
• Primary completion: 2019-01-01
• Completion: 2019-01-01
• First posted: 2017-12-12
• Last updated: 2019-02-15

Locations

1 site across 1 country: France